Relmada Therapeutics (RLMD) Change in Accured Expenses (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Change in Accured Expenses data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 28.94% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$664189.0, a 79.29% increase from a year earlier, with the FY2025 full-year figure at -$1.3 million, up 48.61% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.6 million, down from $1.1 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for RLMD reached as high as $6.6 million in Q2 2022 and fell as low as -$3.1 million in Q4 2022.
• Historically, Change in Accured Expenses has averaged -$33305.9 across 5 years, with a median of -$193775.0 in 2025.
• Across the five-year window, Change in Accured Expenses surged 664.92% in 2022 and tumbled 1143.14% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$3.1 million in 2022, then soared by 199.33% to $3.1 million in 2023, then sank by 86.57% to $419607.0 in 2024, then soared by 168.13% to $1.1 million in 2025, then plunged by 238.6% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.6 million in Q1 2026, $1.1 million in Q4 2025, and -$36140.0 in Q3 2025.